Taxotere (Gastric Cancer) - Analysis and Forecasts to 2020


#28403

24pages

GlobalData

$ 2000

In Stock


GlobalDatas pharmaceuticals report, Taxotere (Gastric Cancer) - Analysis and Forecasts to 2020 provides Taxotere sales estimates for US, EU5 and Japan . In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2002-2020). The report also includes information on Oncology's Disease market. This report is built using data and information sourced from GlobalDatas proprietary databases, primary and secondary research using Companys corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts.

Scope

  • Therapy area profile including patient population for the US, EU5 and Japan (seven major markets)
  • Analysis and review of Taxotere including sales data
  • Qualitative and quantitative assessment of market space
  • Analysis of the trends, drivers and restraints shaping and defining the markets
  • In-depth analysis of Taxotere including efficacy, safety, pricing, competition and other details which influence its sales potential
  • Detailed sales forecast for 2002-2020 for Taxotere in each of the US, EU5 and Japan markets 

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of competition by understanding the changing competitive landscape
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of the drugs performance 
  • Examine the historical sales performance of a drug in seven major markets
  • Obtain sales forecast for currently marketed/pipeline drug for 2011-2020 for all seven major markets
Table of Contents

1 Table of contents 2
1.1 List of Tables 2
1.2 List of Figures 2

2 Introduction 4
2.1 Gastric Cancer Market 4
2.2 Gastric Cancer Disease 4
2.3 GlobalData Pipeline Report Guidance 6

3 Gastric Cancer Disease: Market Characterization 7
3.1 Gastric Cancer Disease Market 7
3.2 Gastric Cancer Disease Market Forecasts and CAGR 7
3.3 Gastric Cancer Disease Market Characteristics 8
3.3.1 High Prevalence 8
3.3.2 High Incidence 8
3.3.3 Low Initial Diagnosis Rate 9
3.3.4 High Mortality Rate 9

4 Tumor Node Metastases(TNM) Classification of gastric cancer 10

5 Taxotere 13

5.1 Introduction 13
5.2 Mechanism of Action 13
5.3 Clinical Study 13
5.4 Approval History of Taxotere 14
5.5 Factors Impacting Sales of Taxotere 14
5.5.1 Gastric Cancer Market 14
5.5.2 Competition 15
5.5.3 Better Efficacy 15
5.5.4 Poor Safety 15
5.6 Drug Risk Benefit Score 16
5.6.1 Efficacy 16
5.6.2 Safety 16
5.6.3 Compliance 16
5.6.4 Dosing Convenience 16
5.7 Sales forecast 16
5.7.1 Target patient Pool of Taxotere 17
5.7.2 Dosing 18
5.7.3 Market Penetration 18
5.7.4 Annual Cost of Therapy 19
5.7.5 Sales Projections of Taxotere 19

6 Gastric Cancer Market: Appendix 22
6.1 Market Definitions 22
6.2 List of Abberiviations 23
6.3 Research Methodology 23
6.3.1 Coverage 23
6.3.2 Secondary Research 23
6.3.3 Forecasting 23
6.3.4 Number of Patients Approved to take the Drug 24
6.3.5 Net Penetration of Drug 24
6.3.6 Net Annual Dosing 24
6.3.7 Annual Cost of Therapy 24
6.3.8 Primary Research 24
6.3.9 Expert Panels 24
6.4 Contact Us 24
6.5 Disclaimer 24
6.6 Sources 24

Table 1: Gastric Cancer, Global, Estimated Incidences and Mortality, 2008-2030 5
Table 2: Gastric Cancer, Global, Estimated Market Sales ($bn),2009-2020 7
Table 3: Approval and Expiry of Taxotere 14
Table 4: Drug Risk Benefit Score of Taxotere 16
Table 5: Gastric Cancer, Annual Dosage of Taxotere 18
Table 6: Gastric Cancer, Global, Estimated Sales of Taxotere($m), 20022016 19
Table 7: Gastric Cancer, the US, Estimated Sales of Taxotere($m), 20062014 20
Table 8: Gastric Cancer, the UK, Estimated Sales of Taxotere($m), 20062014 21
Table 9: Gastric Cancer, France, Estimated Sales of Taxotere($m), 20062014 21
Table 10: Gastric Cancer, Germany, Estimated Sales of Taxotere($m), 20062014 22
Table 11: Gastric Cancer, Italy, Estimated Sales of Taxotere($m), 20062014 22
Table 12: Gastric Cancer, Spain, Estimated Sales of Taxotere($m), 20062014 23
Table 13: Gastric Cancer, Japan, Estimated Sales of Taxotere($m), 20022016 23
Figure 1: Percentage Distribution of Top 20 Cancers 4
Figure 2: Fatality = [(%Distribution of Incidence) (% Distribution Mortality )] of Top 20 Cancers 5
Figure 3: Per Capita Cigarette Consumption, the US,1976-2006 6
Figure 4: Gastric Cancer, Global, Estimated Market Sales ($m),2009-2020 7
Figure 5: Oncology, Global, Estimated Incidence(million),2008-2030 8
Figure 6: Gastric Cancer, Global, Estimated Incidence (million),2008-2030 9
Figure 7: Broad Classification of Gastric Cancer in the US and EU-5 10
Figure 8: Broad Classification of Gastric Cancer in Japan 10
Figure 9: Detailed TNM Classification 11
Figure 10: Classification of Gastric Cancer in the US and EU-5 12
Figure 11: Classification of Gastric Cancer in Japan 12
Figure 12: Phase III results, Taxotere + Cisplatin + Fluorouracil 14
Figure 13: Taxotere Efficacy 15
Figure 14: Drug Model Diagram of Taxotere in the US and EU-5 17
Figure 15: Drug Model Diagram of Taxotere in Japan 18
Figure 16: Gastric Cancer, Global, Estimated Sales of Taxotere($m), 20022016 19
Figure 17: Gastric Cancer, the US, Estimated Sales of Taxotere($m), 20062014 20
Figure 18: Gastric Cancer, the UK, Estimated Sales of Taxotere($m), 20062014 20
Figure 19: Gastric Cancer, France, Estimated Sales of Taxotere($m), 20062014 21
Figure 20: Gastric Cancer, Germany, Estimated Sales of Taxotere($m), 20062014 21
Figure 21: Gastric Cancer, Italy, Estimated Sales of Taxotere($m), 20062014 22
Figure 22: Gastric Cancer, Spain, Estimated Sales of Taxotere($m), 20062014 22
Figure 23: Gastric Cancer, Japan, Estimated Sales of Taxotere($m), 20022016 23